Literature DB >> 25245766

A nomogram to predict disease-free survival after surgical resection of GIST.

Danielle A Bischof1, Yuhree Kim, Ramy Behman, Paul J Karanicolas, Fayez A Quereshy, Dan G Blazer, Shishir K Maithel, T Clark Gamblin, Todd W Bauer, Timothy M Pawlik.   

Abstract

BACKGROUND: Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. Adjuvant imatinib therapy has resulted in improved disease-free survival (DFS) following resection of primary GIST. The aim of our study was to create a nomogram to predict DFS following resection of GIST.
METHOD: Using a multi-institutional cohort of patients who underwent surgery for primary GIST at 7 academic hospitals in the USA and Canada between January 1998 and December 2012, a multivariable Cox proportional hazards model predicting DFS was created using backward stepwise selection. A nomogram to predict DFS following surgical resection of GIST was constructed with the variables selected in the multivariable model. We tested nomogram discrimination by calculating the C-statistic and compared the nomogram to four existing GIST prognostic stratification systems.
RESULTS: A total of 365 patients who underwent surgery for primary GIST was included in the study. Using backward stepwise selection, sex, tumor size, tumor site, and mitotic rate were selected for incorporation into the nomogram. The nomogram demonstrated superior discrimination compared to the NIH criteria, modified NIH criteria, and Memorial Sloan-Kettering Nomogram and had similar discrimination to the Miettinen criteria (C-statistic 0.77 vs 0.73, 0.71, 0.71, and 0.78, respectively).
CONCLUSION: Four independent predictors of recurrence following surgery for primary GIST were used to create a nomogram to predict DFS. The nomogram stratified patients into prognostic groups and performed well on internal validation.

Entities:  

Mesh:

Year:  2014        PMID: 25245766      PMCID: PMC4659361          DOI: 10.1007/s11605-014-2658-2

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  21 in total

1.  Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up.

Authors:  Markku Miettinen; Leslie H Sobin; Jerzy Lasota
Journal:  Am J Surg Pathol       Date:  2005-01       Impact factor: 6.394

Review 2.  Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.

Authors:  F E Harrell; K L Lee; D B Mark
Journal:  Stat Med       Date:  1996-02-28       Impact factor: 2.373

3.  Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS).

Authors:  Javier Martín; Andrés Poveda; Antonio Llombart-Bosch; Rafael Ramos; José A López-Guerrero; Javier García del Muro; Joan Maurel; Silvia Calabuig; Antonio Gutierrez; José L González de Sande; Javier Martínez; Ana De Juan; Nuria Laínez; Ferrán Losa; Valentín Alija; Pilar Escudero; Antonio Casado; Paula García; Pilar García; Remei Blanco; José M Buesa
Journal:  J Clin Oncol       Date:  2005-09-01       Impact factor: 44.544

4.  Gastrointestinal stromal tumors in Iceland, 1990-2003: the icelandic GIST study, a population-based incidence and pathologic risk stratification study.

Authors:  Geir Tryggvason; Hjörtur G Gíslason; Magnús K Magnússon; Jón G Jónasson
Journal:  Int J Cancer       Date:  2005-11-01       Impact factor: 7.396

Review 5.  Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts.

Authors:  Heikki Joensuu; Aki Vehtari; Jaakko Riihimäki; Toshirou Nishida; Sonja E Steigen; Peter Brabec; Lukas Plank; Bengt Nilsson; Claudia Cirilli; Chiara Braconi; Andrea Bordoni; Magnus K Magnusson; Zdenek Linke; Jozef Sufliarsky; Massimo Federico; Jon G Jonasson; Angelo Paolo Dei Tos; Piotr Rutkowski
Journal:  Lancet Oncol       Date:  2011-12-06       Impact factor: 41.316

6.  One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.

Authors:  Heikki Joensuu; Mikael Eriksson; Kirsten Sundby Hall; Jörg T Hartmann; Daniel Pink; Jochen Schütte; Giuliano Ramadori; Peter Hohenberger; Justus Duyster; Salah-Eddin Al-Batran; Marcus Schlemmer; Sebastian Bauer; Eva Wardelmann; Maarit Sarlomo-Rikala; Bengt Nilsson; Harri Sihto; Odd R Monge; Petri Bono; Raija Kallio; Aki Vehtari; Mika Leinonen; Thor Alvegård; Peter Reichardt
Journal:  JAMA       Date:  2012-03-28       Impact factor: 56.272

7.  Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden.

Authors:  Bengt Nilsson; Per Bümming; Jeanne M Meis-Kindblom; Anders Odén; Aydin Dortok; Bengt Gustavsson; Katarzyna Sablinska; Lars-Gunnar Kindblom
Journal:  Cancer       Date:  2005-02-15       Impact factor: 6.860

8.  An evaluation of 2537 gastrointestinal stromal tumors for a proposed clinical staging system.

Authors:  Charles E Woodall; Guy N Brock; Jie Fan; Jerome A Byam; Charles R Scoggins; Kelly M McMasters; Robert C G Martin
Journal:  Arch Surg       Date:  2009-07

Review 9.  Diagnosis of gastrointestinal stromal tumors: A consensus approach.

Authors:  Christopher D M Fletcher; Jules J Berman; Christopher Corless; Fred Gorstein; Jerzy Lasota; B Jack Longley; Markku Miettinen; Timothy J O'Leary; Helen Remotti; Brian P Rubin; Barry Shmookler; Leslie H Sobin; Sharon W Weiss
Journal:  Hum Pathol       Date:  2002-05       Impact factor: 3.466

10.  Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.

Authors:  Ronald P Dematteo; Karla V Ballman; Cristina R Antonescu; Robert G Maki; Peter W T Pisters; George D Demetri; Martin E Blackstein; Charles D Blanke; Margaret von Mehren; Murray F Brennan; Shreyaskumar Patel; Martin D McCarter; Jonathan A Polikoff; Benjamin R Tan; Kouros Owzar
Journal:  Lancet       Date:  2009-03-18       Impact factor: 79.321

View more
  10 in total

1.  Significance of Primary Malignant Tumors on the Outcome of Patients With Resected Gastrointestinal Stromal Tumors.

Authors:  Shuzo Kohno; Hiroaki Aoki; Masaichi Ogawa; Kazuhiko Yoshida; Katsuhiko Yanaga
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

2.  Clinicopathological and Prognostic Analysis of Primary Gastrointestinal Stromal Tumor Presenting with Gastrointestinal Bleeding: a 10-Year Retrospective Study.

Authors:  Zhijie Yin; Jinbo Gao; Weizhen Liu; Cheng Huang; Xiaoming Shuai; Guobin Wang; Kaixiong Tao; Peng Zhang
Journal:  J Gastrointest Surg       Date:  2017-03-08       Impact factor: 3.452

Review 3.  Asian consensus guidelines for gastrointestinal stromal tumor: what is the same and what is different from global guidelines.

Authors:  Toshirou Nishida
Journal:  Transl Gastroenterol Hepatol       Date:  2018-02-08

Review 4.  Standard Approach to Gastrointestinal Stromal Tumors - Differences between China and Europe.

Authors:  Lin Tu; Peter Hohenberger; Heike Allgayer; Hui Cao
Journal:  Visc Med       Date:  2018-10-19

5.  Outcomes After Surgical Resection Differ by Primary Tumor Location for Metastatic Gastrointestinal Stromal Tumors (GISTs): a Propensity Score Matching Population Study.

Authors:  Apostolos Gaitanidis; Michail Alevizakos; Alexandra Tsaroucha; Michail Pitiakoudis
Journal:  J Gastrointest Cancer       Date:  2019-12

6.  Comparison of Different Risk Classification Systems in 558 Patients with Gastrointestinal Stromal Tumors after R0-Resection.

Authors:  Michael Schmieder; Doris Henne-Bruns; Benjamin Mayer; Uwe Knippschild; Claudia Rolke; Matthias Schwab; Klaus Kramer
Journal:  Front Pharmacol       Date:  2016-12-27       Impact factor: 5.810

7.  Comparison of prognostic prediction models for rectal gastrointestinal stromal tumor.

Authors:  Liu Jiaxin; Zhou Peiyun; Tang Zheng; Yuan Wei; Shen Shanshan; Ren Lei; Xing Zhengwen; Fang Yong; Gao Xiaodong; Xue Anwei; Shen Kuntang; Hou Yingyong
Journal:  Aging (Albany NY)       Date:  2020-06-20       Impact factor: 5.682

8.  Nomograms for predicting long-term overall survival and cancer-specific survival in lip squamous cell carcinoma: A population-based study.

Authors:  Chuan-Yu Hu; Zhen-Yu Pan; Jin Yang; Xiu-Hong Chu; Jun Zhang; Xue-Jin Tao; Wei-Min Chen; Yuan-Jie Li; Jun Lyu
Journal:  Cancer Med       Date:  2019-05-21       Impact factor: 4.452

9.  A novel nomogram for predicting liver metastasis in patients with gastrointestinal stromal tumor: a SEER-based study.

Authors:  Guowei Zhou; Keshuai Xiao; Guanwen Gong; Jiabao Wu; Ya Zhang; Xinxin Liu; Zhiwei Jiang; Chaoqun Ma
Journal:  BMC Surg       Date:  2020-11-25       Impact factor: 2.102

10.  Clinicopathological Features and Prognosis of Primary GISTs with Tumor Rupture in the Real World.

Authors:  Toshirou Nishida; Haruhiko Cho; Seiichi Hirota; Toru Masuzawa; Gaku Chiguchi; Toshimasa Tsujinaka
Journal:  Ann Surg Oncol       Date:  2018-05-11       Impact factor: 5.344

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.